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Summary Effectiveness of recombinant DNA (rDNA) human interferon alpha 2 (IFN alpha 2) in advanced
breast cancer was evaluated in 14 patients who had received prior endocrine and/or cytotoxic therapy. After
randomization, 7 patients received IFN alpha 2 two million IUm-2day- 1, s.c., 3 times a week (schedule 1)
and 7 patients received 50 million IUm-2day-', i.v., for 5 consecutive days, every 3 weeks (schedule 2).
Treatment duration was 4-21 weeks in schedule 1 and 6-24 weeks (2-8 courses) in schedule 2. Regressions
were not achieved with either schedule. Treatment was associated with significant toxicity and was more
severe in schedule 2. Dose limiting toxicities were leukopenia, elevation of liver enzymes, hyperglycemia and
fatigue.
Serum IFN activity was low or undetectable in patients on schedule 1 and high in patients on schedule 2.
At 24h, serum IFN activity was detectable in only 1/6 patients on schedule I as compared to 3/7 patients on
schedule 2. IFN neutralizing factors were detected in the serum of only 1 patient prior to treatment but none
were detected in any of the patients during or after discontinuation of treatment (4-24 weeks). IFN alpha 2
increased the expression of both HLA class 1 antigens and /12 microglobulin in peripheral blood lymphocytes
in vivo. This effect was dose related.
Response to human interferon alpha (IFN alpha)
has been noted in advanced breast cancer in phase
I trials (Gutterman et al., 1980; Sherwin et al.,
1982; Horning et al., 1982). Recombinant DNA
(rDNA) human IFN alpha 2 (IFN alpha 2) is a
highly purified single subtype in IFN alpha with a
specific activity equal to or greater than
108IUMmg- protein. In this paper we report the
results of a trial which evaluated the efficacy of
IFN alpha 2 in two treatment schedules - a low
dose continuous subcutaneous therapy and a high
dose pulsed intravenous therapy, in advanced
breast cancer. Data obtained on the
pharmacokinetics, on the development of serum
neutralizing factors to IFN alpha 2 and on the
effect of IFN alpha 2 on the level of expression of
HLA class 1 antigens and /2 microglobulin in
peripheral blood lymphocytes are also presented.
Materials and methods
Female patients with histologically confirmed,
evaluable, progressive advanced breast cancer
refractory to standard endocrine and/or cytotoxic
therapy were considered for the trial. All had a
complete clinical examination with measurements
and/or photographs of lesions, full blood counts,
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blood biochemistry, chest radiograph,
electrocardiogram and isotopic bone scan with
radiographs of regions of increased radionucleide
uptake; a liver scan was performed if indicated.
Baseline lesions were selected for serial assessment.
Patients were eligible for the trial if the following
criteria were fulfilled: Performance status
(Karnofsky) . 50%; adequate cardiovascular,
hepatic [plasma bilirubin <2N (N=upper limit of
the normal range) and serum aspartate amino-
transferase (AST/SGOT) <2.5N], renal (plasma
creatinine <N) and bone marrow (hemoglobin
.8gdl-1, white blood cell count 23xl09l1-
and platelets .75x l0911) function; and no
antimitotic therapy or hormone therapy (except
corticosteroids at a physiological dose) within
past 4 weeks (6 weeks for prior mitomycin C).
Patients were excluded if they had: Non-
carcinomatous tumours of the breast, a second
malignancy (except localised squamous or basal cell
carcinomas of the skin and adequately cone
biopsied in situ carcinoma of the cervix), central
nervous system metastases, serious concomitant
non-malignant disease or previous IFN therapy.
The selected patients were then randomized to
one of two treatment schedules:
1. IFN alpha 2, 2x 106IUm-2day-1, s.c., 3 times
a week.
2. IFN alpha 2, 50 x Il6IU m-2day-1, in 50ml of
saline, given over 30min, i.v., for 5 consecutive
days, every 3 weeks.
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Treatment was continued until disease
progression or unacceptable toxicity was
encountered. Responses were assessed by UICC
criteria (Hayward et al., 1977).
Pharmacokinetics
Blood samples were drawn at 0, 1, 2, 4, 8, 24, 36
and 48 h for patients on schedule 1 and at 0, 1/2, 1,
2, 4, 8, 24h for patients on schedule 2; during the
first week or course of treatment. Serum IFN
activity was estimated by the measurement of the
inhibition of Semliki forest viral RNA synthesis in
human WISH or BT 20 cells. The assay was
standardized against the British reference standard
for human IFN alpha 69/19 (National Institute of
Biological Standards and Controls, London, UK).
Level ofexpression ofHLA class 1 antigens and#2
microglobulin in peripheral blood lymphocytes
Blood samples were obtained before and on days 1,
3 and 5 during the first week or course of therapy.
The levels of HLA class 1 antigens and 12
microglobulin were assayed using monoclonal anti
HLA-ABC and anti 12 microglobulin antibodies.
IFN neutralizingfactors
Serum samples obtained prior to, at intervals of
four weeks during and at the end of treatment were
screened for IFN neutralizing factors by the assay
of the amount of IFN activity (by a
immunoradiometric assay and a bioassay)
recovered after the addition of a known amount of
IFN alpha 2 to the serum samples. IFN
neutralizing factors were considered to be present if
the amount of IFN activity recovered was <50%.
Results
Fourteen patients were entered into the trial, 7 were
randomized to schedule 1 and 7 to schedule 2.
Table I lists the characteristics, previous treatments
and sites of disease for patients on each schedule.
All patients had received prior endocrine and/or
cytotoxic therapy.
Toxicity oftherapy
(Tables II and III)
The side effects were more frequent and severe in
schedule 2. Patients on schedule 1 developed some
degree of tolerance to these side effects while
patients on schedule 2 developed little, if any,
similar tolerance. Raynaud's phenomenon noted by
a patient on schedule 1 during the seventh week of
her therapy disappeared after IFN treatment was
Table I Patient characteristics, previous treatments and
sites ofdisease
Patient characteristics
Schedule
No. of pts.
Age at start of IFN
median (range) yrs
Disease duration
median (range) yrs
1
7
2
7
55 (39-63) 62 (50-70)
5.3 (1.7-22.5) 4.0 (1.0-18.7)
Previous systemic treatmentfor breast cancer
Chemotherapy only
Chemotherapy and
endocrine therapy
Endocrine treatmentsa
per patient, median
(range)
Chemotherapy regimens
per patient, median
(range)
Sites ofdisease
Soft tissue only
Viscera only
Soft tissues
and viscera
Soft tissue, viscera
and bone
1
6
2 (04)
2(1-3)
3
1
0
3
6
1 (0-3)
2 (1-3)
5
0
aPrimary, secondary or tertiary endocrine treatment.
stopped. The patient on schedule 2 who developed
cardiac failure during the third course of treatment
had no clinically evident cardiac disease at entry
into the trial but had received adriamycin and
mitoxantrone (cumulative dose 540mgm 2 and
50mgm-2 respectively) previously. No arrhythmias
or evidence of myocardial infarction were found in
serial electrocardiograms but global left ventricular
dysfunction with a focal area of akinesis at the apex
was found on a gated isotope angiocardiogram
suggesting that a cardiomyopathy±myocardial
infarction was the cause of cardiac failure. The
patient on schedule 2 who became hyperglycemic
was not known to have diabetes before treatment
with IFN. A patient on schedule 2 with mild
diabetes mellitus and stable blood glucose levels
during treatment, developed peripheral neuropathy
confirmed by electromyography and nerve
conduction studies after receiving 8 courses of IFN
alpha 2 in 24 weeks which continued to progress
for 6 months after stopping IFN but resolved in the
subsequent 6 months. In schedule 1 there were no
dose reductions except for a temporary break of 2
weeks in therapy in 1 patient because of fatigue
while in schedule 2 dose reduction was necessary in
all patients to avoid serious leucopenia (In 26/27rDNA IFN ALPHA 2 IN ADVANCED BREAST CANCER 57
Table II Toxicity - Incidence
1 2
Schedule No. ofpts (%) No. ofpts (%)
General
Fever (>37.5°C), chills
and rigors, headache,
myalgia and backpain
Fatigue
Somnolence
Anorexia, nausea
and vomiting
Diarrhoea
Hematology
Depression ofhemoglobin
(< 10.9gdl-1)
Depression ofWBC counts
(<3.9 x 1091-1)
Depression ofgranulocytes
(< 1.9 x 1091-1)
Depression ofplatelets
(< 100 x 1091-1)
3-5 (43-71)
7 (100)
2 (29)
4-5 (57-71)
1 (14)
2 (29)
4 (57)
3 (43)
0
4-7 (57-100)
7 (100)
7 (100)
6-7 (86-100)
3 (43)
5 (71)
7 (100)
7 (100)
0
Liverfunctions
Elevation of serum AST
(21.26 Na) 4 (57) 7 (100)
Elevation of serum gamma GT
(.1.26Na) 7 (100) 7 (100)
Elevation of alk phos
(>1.26Na) 1 (14) 1 (14)
Other: Schedule 1 - Raynaud's phenomenon 1 pt; Schedule 2 -
Cardiac failure 1 pt, hyperglycemia 1 pt and peripheral neuropathy 1
pt.
Toxicity was graded (0-4) according to WHO. criteria (WHO,
1979). This Table shows the number of patients in whom a particular
toxicity (grade >1) was noted at least once during the course of
therapy.
aN Upper limit of normal, AST (SGOT) - Aspartate
aminotransferase, gamma GT - gamma glutamyl transpeptidase and
alk phos - alkaline phosphatase.
courses, median actual cumulative dose expressed
as % projected dose of IFN alpha 2 received by
patients was 70.3% with a range of 51.7 to 82.3%.
The depressed leucocyte counts returned to normal
in 3 to 7 days after a course of treatment) and in 2
patients an additional reason for dose reduction
was either hyperglycemia or marked elevation
serum AST. Treatment had to be stopped, in 2
patients on schedule 1 because of a progressive rise
in the levels of serum AST and gamma glutamyl
transpeptidase (gamma GT) and in 1 patient on
schedule 2 because of cardiac failure. Two patients
(1 in each schedule) needed transfusion of red cells
for anemia and 2 patients on schedule 2 had an
infective episode soon after a course of IFN alpha 2
which responded to antibiotics.
Response
All 14 patients were evaluable for response. The
treatment duration was 9 (median) and 4-21
(range) weeks for the 7 patients on schedule 1. The
disease progressed on treatment in all patients. The
7 patients on schedule 2 received 3 (median) and 2-
8 (range) courses of IFN alpha 2 in 6-24 weeks.
The disease progressed on treatment in 6 while in 1
patient the disease remained stable after 8 courses
(in 24 weeks) of IFN alpha 2.
Subsequent course ofpatients
Nine (5 and 4, schedules 1 and 2 respectively)
patients have died of progressive disease after
discontinuing treatment with IFN alpha 2. Two out58 N. PADMANABHAN et al.
Table III Toxicity - Se
Schedule
Fever, chills and rigors,
headache, myalgia
and backpain
Anorexia, nausea
and vomiting
Fatigue
Depression of hemoglobin
Depression ofwhite
blood cell count
Depression of
granulocyte count
Depression of
platelet count
Elevation of serum AST
Elevation of serum
gamma GT
Elevation of serum
alk phos
verity Effect ofIFN alpha 2 on the level ofexpression of
HLA class I antigens and/2 microglobulin in
1 2 peripheral blood lymphocytes
Data was obtained in 6 patients on schedule 1 and
0.4-1.3 0.7-2.0 in 7 patients on schedule 2. Only 1 patient on
schedule 1 had a twofold increase in the levels of
0.7-1.4 1.6-1.9 both HLA class 1 antigens and /2 microglobulin.
2.1 1.7 In patients on schedule 2, 6 had a threefold increase
0.4 0.9 in the levels of HLA class 1 antigens and all 7 had
1.0 2.7 three to sixfold increase in the level of /32
1.0 2.7 microglobulin.
0.4 2.4
0 0
0.6 2.4
1.7 2.1
0.1 0.3
Severity of toxicity experienced by patients during the
course of treatment expressed on a weighted severity scale.
Toxicity graded (0-4) according to the WHO criteria
(WHO, 1979), where no such criteria exist grading was
from 0 (no symptom) to 4 (very severe toxicity). The
worst grade of the side effect experienced by each patient
during the course of therapy was taken and the weighted
severity was calculated as follows:
Weighted severity=1 (no. of patients reporting reac-
tion x severity)/no. ofpatients in the group.
AST (SGOT) - aspartate aminotransferase, gamma GT
- gamma glutamyl transpeptidase and alk phos - alkaline
phosphatase.
of 7 patients had partial responses to further
endocrine treatment (duration of response 5 and 7
mths, 1 pt to prednisolone and 1 pt to
aminoglutethimide). Four out of 12 patients had
partial responses to further chemotherapy (duration
of response median 4.5 mths and range 3 to 6 mths,
1 pt to adriamycin and 3 pts to mitomycin C with
vinblastine).
Pharmacokinetics
Pharmacokinetic data was obtained in 6 patients on
schedule 1 and in 7 patients on schedule 2 during
the first week or course of therapy. In patients on
schedule 1 the levels of serum IFN activity were
either undetectable (1 pt) or low (5 pts). The levels
rose gradually to a peak (2.5-25IUml-1) between 2
and 8h. At 24h only one patient had detectable
serum IFN activity (6IUml 1). In patients on
schedule 2 the levels of serum IFN activity rose
sharply with a peak (280-3904 IUml-) between
1/2 and 2h and declined rapidly by 4h. However,
serum IFN activity was still detectable in 3 patients
(62-256IUml-1) at 24h.
IFN neutralizingfactors
Only 1 patient out of 14 had detectable IFN
neutralizing factors in her serum prior to treatment
with IFN alpha 2 but none at 4 weeks (serum IFN
activity in this patient during the first course of
treatment ranged from 256-1826 IUml -1 with
detectable activity of 256 IUml- I at 34h). None of
the patients had detectable IFN neutralizing factors
in the serum samples obtained during and after
treatment (median 10 weeks, range 4-24 weeks).
Discussion
Treatment with IFN alpha 2 was associated with
significant toxicity which was dose related.
Depression of bone marrow and hepatic
dysfunction were the major dose limiting factors.
Central nervous system toxicity was limited to
somnolence and the serious toxicity noted with the
use of much higher doses of IFN was not seen
(Rohatiner et al., 1983; Nethersell et al., 1984).
Hyperglycemia (data on file with Schering-Plough
corp.), Raynaud's phenomenon (Sangster et al.,
1983), cardiac toxicity (Oldham, 1983), peripheral
neuropathy (Gutterman et al., 1982) and other
toxicities (Gutterman et al., 1980, 1982; Sherwin et
al., 1982, 1983; Horning et al., 1982; Borden et al.,
1982; Edelstein et al., 1983) noted in this trial have
been reported previously.
The lack of antitumour activity for IFN alpha 2
as noted in this trial differs from the results of
studies in vitro, in animal tumour model systems
and from the results of other clinical trials
(Gutterman et al., 1980; Sherwin et al., 1982;
Horning et al., 1982; Borden et al., 1982). Two
possible explanations can be given to account for
this discrepancy. First, it is possible that a mixture
of species of IFNs alpha is more active than a
single species, as the phase 2 trial (Borden et al.,
1982) which evaluated leukocyte derived IFN (a
mixture of species of IFNs alpha) in advanced
breast cancer found 5 partial responses in 23
patients (median duration of response 59 days,
range 14-176 days) while the trials which evaluatedrDNA IFN ALPHA 2 IN ADVANCED BREAST CANCER 59
a single pure species of IFN alpha found none
(current trial and Sherwin et al., 1983 - evaluated
rDNA human IFN alpha A which is essentially
identical but differs by one amino acid from rDNA
IFN alpha 2, see Pestka, 1983).
Second, it is possible that the previous cytotoxic
therapy received by patients in this trial had a role
in determining the resistance of their tumours to
IFN. This explanation is supported by the fact that
all the patients in this trial and in the trial reported
by Sherwin et al. (1983), had received prior
cytotoxic + endocrine therapy whereas patients
included in the trial reported by Borden et al.
(1982), had either received no prior systemic
therapy or were responders to prior endocrine
therapy only and in the trial reported by Nethersell
et al. (1984, evaluated rDNA human IFN alpha A)
the only 2 responders (partial responses, noted at 4
wks not maintained at 12 wks) were patients who
had not received prior cytotoxic therapy but were
responders to prior endocrine therapy. The
observations that: (a) enough serum IFN activity
was present in all patients to produce some degree
of toxicity, (b) serum IFN activity was detectable in
12 patients out of the 14, (c) 8 patients had changes
in the level of expression of HLA class 1 antigens
and/or #2 microglobulin and (d) IFN neutralizing
factors were noted in only 1 patient; suggest that
tumour resistance to IFN alpha 2 is the probable
explanation for the lack of response noted in this
trial. The observation that useful responses were
obtained to further chemo and endocrine therapy
suggests that IFN alpha 2 did not have an adverse
influence on the outcome of subsequent treatment.
The increase in the level of expression of HLA
class 1 antigens and f2 microglobulin in peripheral
blood lymphocytes induced by IFN alpha 2
confirms that these changes seen in vitro (Hokland
et al., 1981), occur in vivo. It may be possible to
define an optimum dose for IFN using this system
as this effect seems to be dose related.
The lack of response to IFN alpha 2 in the 14
patients evaluated in this trial suggests that the rate
of response to this drug when used as a single agent
in advanced breast cancer in either dose schedule, is
unlikely to be greater than 35% in patients who
have received prior cytotoxic + endocrine therapy.
If these results are considered in conjunction with
the results obtained (in patients who had received
prior cytotoxic + endocrine therapy) in other
phase 2 trials (Sherwin et al., 1983; Nethersell et al.,
1984) the response rate for IFN alpha 2 in this
defined set of patients is unlikely to be greater than
20%. As some studies suggest synergism between
IFN and cytotoxic drugs (Balkwill & Moodie,
1984), the future role of this drug in advanced
breast cancer will have to be defined by trials to
evaluate such combinations.
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